| |
With the emergence of precision medicine and its focus on customizing treatment to individual patients, it may be possible to reduce the time to diagnosis for rare conditions, enabling identification and intervention at earlier stages of the disease – a hope that is new for rare disease patients. Explore this and more in our latest blog. Premier Research. Built for Biotech℠.
|
|
Today's Big NewsMar 22, 2023 |
| By Max Bayer Biohaven is using business development to once again bolster its pipeline, this time tacking on a brain-penetrating treatment for neuroinflammatory diseases slated to hit the clinic within a year. Biohaven has signed a $970 million agreement with Highlightll Pharma for ex-China rights to the drug. |
|
|
|
By Gabrielle Masson Novo Nordisk and Dewpoint Therapeutics are partnering up in efforts to treat insulin resistance and diabetic complications, with the Danish pharma offering up the possibility of $745 million in biobucks. |
By Nick Paul Taylor 89bio is turning up the heat on Akero Therapeutics. In a phase 2b clinical trial, 89bio linked its FGF21 analog to reduced liver scarring in patients with nonalcoholic steatohepatitis (NASH) to stay hot on the heels of Akero’s rival drug candidate. |
Sponsored by DrugBank Data rich but quality poor. Massive amounts of disorganized data might be the final roadblock to unlocking the potential of data-centric AI. |
By Nick Paul Taylor Astellas Pharma’s zolbetuximab has gone two for two, chalking up a second phase 3 win to cement its status as the front-runner in the race to deliver a drug against one of the hottest targets in cancer today. |
By James Waldron Altimmune’s share price took a battering yesterday as investors reacted to interim data from its obesity drug that revealed a high level of discontinuations. But one analyst group says the drug could still compete with Novo Nordisk’s blockbuster-to-be Wegovy. |
By Gabrielle Masson Things are heating up at Flare Therapeutics, with big names like Pfizer, Eli Lilly and Novartis adding fuel to the biotech’s fire in a new $123 million financing round. |
By Ben Adams If it’s March, it must be #FierceMadness, Fierce Pharma Marketing’s annual take on the March Madness NCAA basketball tournament and bracket mania—with a pharma twist. |
By Andrea Park Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with Alzheimer’s disease, Cognito Therapeutics has now secured a flurry of funding to delve even deeper into the technology. |
By Fraiser Kansteiner The National Institutes of Health (NIH) rejected a petition to exercise so-called march-in authority around Pfizer and Astellas' Xtandi. The same fate befell a similar petition back in 2016 and comes after a trio of U.S. Senators last year pressed Department of Health and Human Services Secretary Xavier Becerra to move forward with the campaign. |
By Teresa Carey This week on "Podnosis," we discuss the importance of nuanced care for neurodivergent adults, given that 20% of the world's population is neurodivergent. We also discuss the landmark $10 billion agreement to settle with CVS and Walgreens and how cases like this can force change in the healthcare industry. |
By Kevin Dunleavy Regeneron has earned an FDA nod for the use of Evkeeza in children ages 5 through 11 with homozygous familial hypercholesterolemia. The ultra-rare genetic condition is characterized by dangerously high levels of bad cholesterol, with treatment options limited for younger children. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the SVB failure, what to expect next and what it all meant for the biotech industry. We also cover Pfizer's big acquisition, insulin prices and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ Don’t miss the opportunity to gain best practices in medical affairs strategy development and ensuring scientific materials are created and shared in a regulatory compliant manner to internal/external stakeholders and thought leaders. Register Today & save $200 from now until April 7th!
|
|
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
